Yeeshen
2021-12-23
..nj
Gilead's Remdesivir Shows Consistent Efficacy In Patients With Comorbidities With Higher Risk for Severe COVID-19<blockquote>吉利德的瑞德西韦在重症COVID-19风险较高的合并症患者中显示出一致的疗效</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":698068925,"tweetId":"698068925","gmtCreate":1640264383477,"gmtModify":1640264383532,"author":{"id":3557700781666328,"idStr":"3557700781666328","authorId":3557700781666328,"authorIdStr":"3557700781666328","name":"Yeeshen","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>..nj</p></body></html>","htmlText":"<html><head></head><body><p>..nj</p></body></html>","text":"..nj","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/698068925","repostId":1175709461,"repostType":4,"repost":{"id":"1175709461","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640261357,"share":"https://www.laohu8.com/m/news/1175709461?lang=zh_CN&edition=full","pubTime":"2021-12-23 20:09","market":"us","language":"en","title":"Gilead's Remdesivir Shows Consistent Efficacy In Patients With Comorbidities With Higher Risk for Severe COVID-19<blockquote>吉利德的瑞德西韦在重症COVID-19风险较高的合并症患者中显示出一致的疗效</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1175709461","media":"Benzinga","summary":"Gilead Sciences Inc announced full results from a Phase 3 study of a three-day course of Veklury (re","content":"<p><b>Gilead Sciences Inc</b> announced full results from a Phase 3 study of a three-day course of Veklury (remdesivir) non-hospitalized COVID-19 patients at high risk for disease progression.</p><p><blockquote><b>吉利德科学公司</b>宣布了一项针对疾病进展高风险非住院COVID-19患者的为期三天的Veklury（remdesivir）3期研究的全部结果。</blockquote></p><p> <ul> <li>Participants receiving Veklury treatment had an 87% reduction in risk for the composite primary endpoint of COVID-19-related hospitalization or all-cause death by Day 28.</li> <li>There was an 81% reduction in the risk for the composite secondary endpoint of COVID-19-related medical visits due to COVID-19 or all-cause death by Day 28 compared to placebo.</li> <li>There was no difference observed in nasopharyngeal SARS-CoV-2 viral load up to Day 7 between groups, indicating that upper respiratory viral loads do not reliably predict treatment outcomes in COVID-19.</li> <li>No deaths were observed in either arm in the study by Day 28.</li> <li>The study includes new subgroup analyses which showed consistent efficacy of Veklury for patients irrespective of their key risk factors for severe COVID-19.</li> <li>Participants with comorbidities had a reduced risk of COVID-19-related hospitalization by Day 28 with Veklury treatment.</li> <li>The safety profile was similar between Veklury and placebo across the variety of outpatient settings in this trial.</li> <li>The most common treatment-emergent adverse events in patients taking Veklury were nausea and headache.</li> <li><b>Price Action:</b> GILD shares closed 0.23% at $72.60 during after-hours trading on Wednesday.</li> </ul></p><p><blockquote><ul><li>到第28天，接受Veklury治疗的参与者新冠肺炎相关住院或全因死亡的复合主要终点风险降低了87%。</li><li>与安慰剂相比，第28天因新冠肺炎或全因死亡导致的新冠肺炎相关医疗就诊的复合次要终点风险降低了81%。</li><li>直到第7天，两组之间的鼻咽新型冠状病毒病毒载量没有差异，表明上呼吸道病毒载量不能可靠地预测新冠肺炎的治疗结果。</li><li>截至第28天，研究中任一组均未观察到死亡。</li><li>该研究包括新的亚组分析，显示Veklury对患者具有一致的疗效，无论其严重新冠肺炎的关键风险因素如何。</li><li>到第28天，有合并症的参与者接受Veklury治疗后，新冠肺炎相关住院的风险降低。</li><li>在本试验中，Veklury和安慰剂在各种门诊环境中的安全性特征相似。</li><li>服用Veklury的患者中最常见的治疗后出现的不良事件是恶心和头痛。</li><li><b>价格走势：</b>周三盘后交易中，GILD股价收盘上涨0.23%，至72.60美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead's Remdesivir Shows Consistent Efficacy In Patients With Comorbidities With Higher Risk for Severe COVID-19<blockquote>吉利德的瑞德西韦在重症COVID-19风险较高的合并症患者中显示出一致的疗效</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead's Remdesivir Shows Consistent Efficacy In Patients With Comorbidities With Higher Risk for Severe COVID-19<blockquote>吉利德的瑞德西韦在重症COVID-19风险较高的合并症患者中显示出一致的疗效</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-23 20:09</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>Gilead Sciences Inc</b> announced full results from a Phase 3 study of a three-day course of Veklury (remdesivir) non-hospitalized COVID-19 patients at high risk for disease progression.</p><p><blockquote><b>吉利德科学公司</b>宣布了一项针对疾病进展高风险非住院COVID-19患者的为期三天的Veklury（remdesivir）3期研究的全部结果。</blockquote></p><p> <ul> <li>Participants receiving Veklury treatment had an 87% reduction in risk for the composite primary endpoint of COVID-19-related hospitalization or all-cause death by Day 28.</li> <li>There was an 81% reduction in the risk for the composite secondary endpoint of COVID-19-related medical visits due to COVID-19 or all-cause death by Day 28 compared to placebo.</li> <li>There was no difference observed in nasopharyngeal SARS-CoV-2 viral load up to Day 7 between groups, indicating that upper respiratory viral loads do not reliably predict treatment outcomes in COVID-19.</li> <li>No deaths were observed in either arm in the study by Day 28.</li> <li>The study includes new subgroup analyses which showed consistent efficacy of Veklury for patients irrespective of their key risk factors for severe COVID-19.</li> <li>Participants with comorbidities had a reduced risk of COVID-19-related hospitalization by Day 28 with Veklury treatment.</li> <li>The safety profile was similar between Veklury and placebo across the variety of outpatient settings in this trial.</li> <li>The most common treatment-emergent adverse events in patients taking Veklury were nausea and headache.</li> <li><b>Price Action:</b> GILD shares closed 0.23% at $72.60 during after-hours trading on Wednesday.</li> </ul></p><p><blockquote><ul><li>到第28天，接受Veklury治疗的参与者新冠肺炎相关住院或全因死亡的复合主要终点风险降低了87%。</li><li>与安慰剂相比，第28天因新冠肺炎或全因死亡导致的新冠肺炎相关医疗就诊的复合次要终点风险降低了81%。</li><li>直到第7天，两组之间的鼻咽新型冠状病毒病毒载量没有差异，表明上呼吸道病毒载量不能可靠地预测新冠肺炎的治疗结果。</li><li>截至第28天，研究中任一组均未观察到死亡。</li><li>该研究包括新的亚组分析，显示Veklury对患者具有一致的疗效，无论其严重新冠肺炎的关键风险因素如何。</li><li>到第28天，有合并症的参与者接受Veklury治疗后，新冠肺炎相关住院的风险降低。</li><li>在本试验中，Veklury和安慰剂在各种门诊环境中的安全性特征相似。</li><li>服用Veklury的患者中最常见的治疗后出现的不良事件是恶心和头痛。</li><li><b>价格走势：</b>周三盘后交易中，GILD股价收盘上涨0.23%，至72.60美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1175709461","content_text":"Gilead Sciences Inc announced full results from a Phase 3 study of a three-day course of Veklury (remdesivir) non-hospitalized COVID-19 patients at high risk for disease progression.\n\nParticipants receiving Veklury treatment had an 87% reduction in risk for the composite primary endpoint of COVID-19-related hospitalization or all-cause death by Day 28.\nThere was an 81% reduction in the risk for the composite secondary endpoint of COVID-19-related medical visits due to COVID-19 or all-cause death by Day 28 compared to placebo.\nThere was no difference observed in nasopharyngeal SARS-CoV-2 viral load up to Day 7 between groups, indicating that upper respiratory viral loads do not reliably predict treatment outcomes in COVID-19.\nNo deaths were observed in either arm in the study by Day 28.\nThe study includes new subgroup analyses which showed consistent efficacy of Veklury for patients irrespective of their key risk factors for severe COVID-19.\nParticipants with comorbidities had a reduced risk of COVID-19-related hospitalization by Day 28 with Veklury treatment.\nThe safety profile was similar between Veklury and placebo across the variety of outpatient settings in this trial.\nThe most common treatment-emergent adverse events in patients taking Veklury were nausea and headache.\nPrice Action: GILD shares closed 0.23% at $72.60 during after-hours trading on Wednesday.","news_type":1,"symbols_score_info":{"GILD":0.9}},"isVote":1,"tweetType":1,"viewCount":3315,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/698068925"}
精彩评论